{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"434"},{"groupId":"OG001","value":"341"}],"units":"Participants"}],"title":"Baseline evaluable participants"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7"},{"groupId":"OG001","value":"26.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"319"}],"units":"Participants"}],"title":"Post-baseline evaluable participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"434"},{"groupId":"OG001","value":"341"}],"units":"Participants"}],"description":"Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).","groups":[{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"OG001","title":"Atezolizumab Monotherapy"}],"paramType":"NUMBER","populationDescription":"The baseline ADA-evaluable population included participants who had a baseline ADA result. The post-baseline ADA-evaluable population included participants who had received at least one dose of the study treatment and who had at least one post-baseline ADA result.","reportingStatus":"POSTED","timeFrame":"Up to approximately 35 months","title":"Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}